What Are These Two Peptides, and Where Do They Come From?

GHK-Cu is a tripeptide, glycine-histidine-lysine, that binds copper and occurs naturally in human plasma, saliva, and urine. Plasma concentrations decline with age, a pattern first described by Loren Pickart in the 1970s. Because it is endogenous, researchers have been able to study its baseline biology in human tissue samples and cell lines for decades, which gives the GHK-Cu literature a somewhat different character than purely synthetic compounds.

BPC-157 stands for Body Protection Compound-157. It is a 15-amino-acid peptide derived from a partial sequence of human gastric juice protein BPC. Unlike GHK-Cu, BPC-157 does not occur freely in the body at measurable circulating levels. It is entirely synthetic and was developed as a research tool, primarily by Croatian researcher Predrag Sikiric and colleagues beginning in the 1990s. The compound has never progressed to a completed Phase III human trial.

Mechanisms: How Does Each Peptide Work at the Cellular Level?

GHK-Cu's mechanism centers on copper transport and gene regulation. The copper ion it carries participates in enzymatic reactions tied to collagen synthesis, antioxidant activity via superoxide dismutase, and angiogenesis. A 2012 analysis by Pickart and Margolina published in the journal Cosmetics examined GHK-Cu's influence on gene expression and reported that the peptide appeared to modulate over 4,000 human genes in microarray studies, including upregulation of genes associated with tissue remodeling and downregulation of genes linked to inflammatory signaling. That figure comes from in-vitro work and should not be read as a clinical outcome.

BPC-157 appears to work through several overlapping pathways. Animal studies have pointed to interactions with the nitric oxide system, upregulation of growth hormone receptor expression in tendon fibroblasts, and modulation of the FAK-paxillin pathway involved in cell migration. A 2018 review by Sikiric et al. in Current Pharmaceutical Design summarized decades of rodent research suggesting BPC-157 influences both peripheral tissue repair and central nervous system signaling. The breadth of proposed mechanisms is notable, and some researchers have flagged it as a reason for caution: a compound claimed to act on many unrelated systems simultaneously warrants more rigorous human data before strong conclusions are drawn.

Evidence Quality: How Do the Research Bases Compare?

GHK-Cu has a larger volume of in-vitro human cell research than BPC-157, partly because its endogenous origin made it easier to study in human tissue contexts. Wound-healing studies using human fibroblast cultures, skin explant models, and small clinical trials in dermatology have been published going back to the 1980s. A 1993 study in the Proceedings of the National Academy of Sciences examined GHK-Cu's effect on wound healing in a controlled human skin model. However, most of these human-adjacent studies are small, often industry-funded, and focused on topical cosmetic applications rather than systemic effects.

BPC-157's evidence base is almost entirely animal-based. The overwhelming majority of published studies use rats or mice, frequently from Sikiric's own research group in Zagreb. A 2021 review in Biomedicines catalogued dozens of rodent studies covering tendon, ligament, bone, gut, and neurological endpoints. The consistency of positive findings across that body of work is scientifically interesting, but the near-total absence of independent replication and the lack of completed human RCTs are significant limitations. One small Phase II trial for inflammatory bowel disease was registered (NCT00281190) but results were never published in a peer-reviewed journal, which is a gap the research community has noted.

Neither compound has a completed, published, large-scale human RCT demonstrating efficacy for any indication. That is the single most important fact for anyone reading vendor marketing materials about either peptide.

Regulatory Status and Legal Classification

GHK-Cu occupies an unusual regulatory position. As a tripeptide, it appears in numerous cosmetic and skincare products sold legally in the United States, where it is regulated as a cosmetic ingredient rather than a drug when applied topically. The FDA has not approved GHK-Cu as a drug for any indication. Injectable or intranasal research-grade GHK-Cu sold by peptide vendors is not FDA-approved and is not equivalent to any approved pharmaceutical.

BPC-157 has no approved pharmaceutical form anywhere in the world. In 2022, the FDA placed BPC-157 on its list of bulk drug substances that may not be used in compounding, effectively restricting licensed compounding pharmacies from including it in preparations. This action followed a review in which the FDA determined there was insufficient evidence of clinical usefulness and raised safety concerns. Research-chemical vendors continue to sell it, but those sales exist outside the pharmaceutical regulatory framework entirely.

The compounding restriction on BPC-157 is a meaningful regulatory distinction between the two compounds. GHK-Cu does not face the same explicit FDA compounding prohibition as of the time of writing, though neither compound should be understood as approved or endorsed by any regulatory agency for therapeutic use.

What Distinguishes Them in Practice for Researchers?

The two peptides are often grouped together in online discussions because both appear in tissue-repair contexts, but their research profiles are genuinely different. GHK-Cu research is concentrated in skin biology, wound healing, and anti-aging dermatology, with a meaningful portion of the evidence coming from human cell studies and small clinical observations. BPC-157 research spans a wider range of tissue types and organ systems, but almost all of it is rodent-based and comes from a narrow cluster of research groups.

Stability and delivery also differ. GHK-Cu is relatively stable in aqueous solution and has been formulated successfully for topical use, which is part of why it reached commercial cosmetic products. BPC-157 is typically studied in injectable or oral forms in animal research, and its stability profile in various delivery formats is less thoroughly characterized in independent literature.

Researchers comparing the two should weigh the depth of the evidence in each compound's primary studied domain against the breadth of claims made by vendors. GHK-Cu has narrower but somewhat better-characterized human-adjacent data in skin contexts. BPC-157 has a wider claimed scope but a thinner human evidence trail across all of those areas.